Home>Topics>Stocks>Impax Laboratories

Impax Laboratories IPXL

  1. All
  2. Commentary
  3. Fund Reports
  4. Headlines
    1. Impax Laboratories' ( IPXL ) CEO George Wilkinson on Q2 2014 Results - Earnings Call Transcript

      Headlines

      Wed, 6 Aug 2014

      Impax Laboratories (NASDAQ: IPXL ) Q2 2014 Earnings Call August 06, 2014 8:30 am ET Executives Mark Donohue - Vice President of Investor Relations and Corporate

    2. Impax Labs updates guidance after Q2 results

      Headlines

      Wed, 6 Aug 2014

      Impax Laboratories ( IPXL +1.3% ) Q2 results : Revenues: $188.1M (+45.1%); Gross Profit: $109.8M (+86.4%); Operating Expenses

    3. Impax Lab beats by $0.22, beats on revenue

      Headlines

      Wed, 6 Aug 2014

      Impax Lab (NASDAQ: IPXL ): Q2 EPS of $0.60 beats by $0.22 . Revenue of $188.1M (+45.1% Y/Y) beats by $32.13M . Press Release Post your comment!

    4. Notable earnings before Wednesday’s open

      Headlines

      Tue, 5 Aug 2014

      CHK , CLH , CMLS , CNP , CONE , CSTE , CTSH , DBD , DISH , DNR , DVN , DWSN , EE , ELOS , GEO , GOV , GWPH , HFC , HNT , INXN , IPXL , ITC , KELYA , LINC , LIOX , MDLZ , MEMP , MVIS , NAVB , NUS , PERI , PH , PKD , POWR , RDC , RL , ROC , SBGI , SE , SEP , SF

    5. FDA reinspects Impax Labs Hayward manufacturing site

      Headlines

      Mon, 4 Aug 2014

      The FDA reinspected Impax Laboratories ' (NASDAQ: IPXL ) Hayward, California manufacturing facility from June 16 to July 31, 2014. In its Form 483, it cited seven observations

    6. U.S. FDA raises concerns about Impax's Taiwanese plant

      Headlines

      Tue, 29 Jul 2014

      July 29 (Reuters) - Impax Laboratories Inc said the U.S. Food and Drug Administration issued "certain observations" after an inspection of the company's manufacturing plant in Taiwan.

    7. Impax shares fall after FDA denies approval to Parkinson's drug

      Headlines

      Tue, 22 Jan 2013

      (Reuters) - Shares of Impax Laboratories Inc fell as much as 10 percent on Tuesday, after U.S. health regulators denied approval to the company's Parkinson's drug and asked for a reinspection of its...

    8. Impax gets FDA warning letter, shares fall

      Headlines

      Mon, 6 Jun 2011

      (Reuters) - Impax Laboratories Inc said it received a warning letter from U.S. health regulators on deficient sampling and testing of drugs at its Hayward, California-based plant, sending the...

    9. Prospects Brighten for Medicis' Solodyn

      Commentary

      Fri, 8 Oct 2010

      competition until late 2011, thanks to several deals with Teva TEVA, Sandoz (a unit of Novartis NVS), Mylan MYL, and Impax IPXL . By paying the generic companies to delay competition, Medicis has lengthened the runway for Solodyn. The firm may have bought

    10. CMSCX Columbia Small Cap Growth I Z Fund Analysis, Report, Research, 5 Star Rating – Morningstar

      Fund Reports

      Wed, 23 Dec 2009

      stocks. Nearly one fourth of this fund's assets are in micro-cap stocks such as top-10 holdings TNS TNS, Impax Laboratories IPXL , and Omnicell OMCL, and its average market cap is less than $1 billion, as opposed to Mid Cap Growth's

    « Prev123Next »
    Content Partners